KRRO

+ Watchlist + Portfolio

Korro Bio, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $13.95
52-Week Range: $5.20 – $55.89
Market Cap: $190.84M
P/E (TTM): —
EPS (TTM): -9.19
Dividend Yield: —

Advanced Metrics

Price/Book: 1.85
PEG Ratio: —
Return on Equity: -97.69%
Return on Assets: -27.95%
Gross Margin: 0.00%
Operating Margin: -3228.34%
Profit Margin: 0.00%
Current Ratio: 9.55
Debt/Equity: 0.41
Total Debt: $42.21M
Free Cash Flow: $-41.39M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $118.02M

KRRO Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$2.27M	$6.39M
Research & Development	$42.20M	$57.25M	$63.64M	$65.58M
Selling, General & Admin	$16.80M	$27.28M	$30.55M	$28.16M
Operating Expenses	$59.00M	$84.53M	$94.18M	$93.73M
Operating Income	-$59.00M	-$84.53M	-$91.91M	-$87.34M
EBITDA	-$56.49M	-$80.90M	-$88.34M	-$83.06M
Pretax Income	-$58.02M	-$81.14M	-$83.44M	-$116.62M
Income Tax	$10.00K	$27.00K	$141.00K	$637.00K
Net Income	-$58.03M	-$81.17M	-$83.58M	-$117.26M
Diluted EPS	-7.25	-53.08	-9.37	-12.48
Diluted Shares	8.00M	1.53M	8.92M	9.40M

KRRO Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$36.33M	$166.15M	$55.64M	$21.82M
Receivables	—	$0.00	$1.70M	$969.00K
Current Assets	$57.08M	$172.73M	$131.53M	$82.37M
Total Assets	$73.74M	$221.66M	$226.24M	$113.51M
Current Liabilities	$8.70M	$19.48M	$14.96M	$11.94M
Total Debt	$3.13M	$33.21M	$44.77M	$43.49M
Total Liabilities	$172.77M	$51.75M	$65.83M	$62.07M
Retained Earnings	-$101.83M	-$183.00M	-$266.59M	-$383.85M
Shareholders' Equity	-$99.03M	$169.91M	$160.41M	$51.44M
Working Capital	$48.38M	$153.25M	$116.57M	$70.44M

KRRO Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$53.65M	-$67.28M	-$60.07M	-$78.56M
Capital Expenditure	-$5.21M	-$7.84M	-$17.90M	-$518.00K
Free Cash Flow	-$58.86M	-$75.12M	-$77.98M	-$79.08M
Depreciation & Amortisation	$2.51M	$3.63M	$3.56M	$4.28M
Stock-Based Compensation	$1.14M	$2.38M	$4.46M	$7.66M
Investing Cash Flow	$11.06M	$11.16M	-$123.35M	$43.99M
Financing Cash Flow	$18.00K	$187.76M	$69.36M	$685.00K
Net Change in Cash	-$42.57M	$131.64M	-$114.07M	-$33.88M

KRRO Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$2.55M	$1.46M	$1.09M	$1.29M	$0.00
Research & Development	$19.74M	$21.03M	$13.82M	$10.98M	$12.95M
Selling, General & Admin	$7.83M	$7.63M	$6.51M	$6.19M	$7.49M
Operating Expenses	$27.57M	$28.66M	$20.33M	$17.18M	$20.44M
Operating Income	-$25.02M	-$27.20M	-$19.24M	-$15.88M	-$20.44M
EBITDA	-$23.80M	-$25.98M	-$18.06M	-$15.23M	-$20.06M
Pretax Income	-$23.39M	-$25.77M	-$18.06M	-$49.41M	-$19.53M
Income Tax	$0.00	$1.00K	$0.00	$636.00K	$95.00K
Net Income	-$23.39M	-$25.77M	-$18.06M	-$50.04M	-$19.63M
Diluted EPS	-2.49	-2.74	-1.92	—	-1.69
Diluted Shares	9.38M	9.39M	9.39M	—	11.60M

KRRO Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$64.14M	$33.61M	$24.16M	$21.82M	$61.70M
Receivables	$1.92M	$1.09M	$820.00K	$969.00K	$0.00
Current Assets	$121.23M	$102.63M	$98.23M	$82.37M	$120.16M
Total Assets	$202.21M	$180.43M	$161.55M	$113.51M	$183.62M
Current Liabilities	$12.88M	$17.17M	$14.64M	$11.94M	$14.79M
Total Debt	$45.19M	$44.63M	$44.67M	$43.49M	$42.88M
Total Liabilities	$63.25M	$65.32M	$62.52M	$62.07M	$63.99M
Retained Earnings	-$289.97M	-$315.74M	-$333.80M	-$383.85M	-$403.47M
Shareholders' Equity	$138.96M	$115.10M	$99.03M	$51.44M	$119.63M
Working Capital	$108.35M	$85.46M	$83.59M	$70.44M	$105.38M

KRRO Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$24.45M	-$19.23M	-$17.18M	-$17.70M	-$16.07M
Capital Expenditure	-$119.00K	-$140.00K	-$175.00K	-$84.00K	-$21.00K
Free Cash Flow	-$24.57M	-$19.37M	-$17.35M	-$17.79M	-$16.09M
Depreciation & Amortisation	$1.23M	$1.23M	$1.18M	$649.00K	$380.00K
Stock-Based Compensation	$1.76M	$2.00M	$1.82M	$2.07M	$2.73M
Investing Cash Flow	$32.78M	-$11.30M	$7.60M	$14.92M	-$32.24M
Financing Cash Flow	$172.00K	$5.00K	$128.00K	$380.00K	$88.21M
Net Change in Cash	$8.50M	-$30.52M	-$9.46M	-$2.41M	$39.90M

Market Snapshot

About

Korro Bio is a biopharmaceutical company pioneering RNA editing therapeutics using proprietary OPERA (Oligonucleotide Promoted Editing of RNA) technology. The company's platform enables precise, programmable editing of RNA to correct disease-causing mutations and modulate protein function. Korro is developing treatments for genetic diseases affecting the liver, central nervous system, and other organs with high unmet medical needs.